Sunday, 20 September 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

CABKA EUR 12W Stock Bearish By 17% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of CABKA EUR 12W (AEX-Index: DSCW2.AS) dropped by a staggering 17.81% in 5 sessions from €0.07 to €0.06 at 02:08 EST on Monday, after five successive sessions in a row of losses. AEX-Index is rising 0.11% to €761.40, after two successive sessions in a row of gains.

CABKA EUR 12W's last close was €0.06, 17.81% below its 52-week high of €0.07.

About CABKA EUR 12W

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CABKA EUR 12W's stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

CABKA EUR 12W's stock is valued at €0.06 at 02:08 EST, way below its 52-week low of €0.07.

More news about CABKA EUR 12W (DSCW2.AS).

Categories

stockMarket

Tags

Stock PricePrice DownMarket Session NowCABKA EUR 12WStock Price DownStock Market NowMarket SessionDSCW2.ASStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com